Core Viewpoint - Changfeng Pharmaceutical (02652.HK) has received a notice of acceptance from the National Medical Products Administration (NMPA) for its clinical trial application of the self-developed fixed combination formulation, Olopatadine Mometasone nasal spray, marking a significant step in its clinical development process [1] Group 1: Product Information - Product Name: Olopatadine Mometasone nasal spray [1] - Application Type: Domestic production drug registration clinical trial [1] - Indication: Treatment of moderate to severe allergic rhinitis symptoms in adults and adolescents aged 12 and above [1] Group 2: Clinical Development - The acceptance of the clinical trial application signifies the product's entry into the regulatory review phase for potential clinical development by NMPA [1] - The clinical research aims to evaluate whether this fixed combination formulation can provide a convenient treatment option for patients whose symptoms are not effectively controlled by single therapies [1] Group 3: Strategic Alignment - This milestone aligns with the company's strategy to establish a differentiated portfolio of respiratory and nasal products [1] - The company intends to leverage its formulation, device integration, and manufacturing capabilities in the field of nasal drug-device combination products [1]
长风药业(02652.HK)：奥洛他定莫米松鼻喷雾剂临床试验申请获NMPA受理